[go: up one dir, main page]

YU60198A - Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf) - Google Patents

Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf)

Info

Publication number
YU60198A
YU60198A YU60198A YU60198A YU60198A YU 60198 A YU60198 A YU 60198A YU 60198 A YU60198 A YU 60198A YU 60198 A YU60198 A YU 60198A YU 60198 A YU60198 A YU 60198A
Authority
YU
Yugoslavia
Prior art keywords
pde
tnf
type
necrosis factor
tumor necrosis
Prior art date
Application number
YU60198A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
PFIZER INC., proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER INC., proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware filed Critical PFIZER INC., proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware
Publication of YU60198A publication Critical patent/YU60198A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na formulu (I) i njene farmaceutski prihvatljive soli gde su R, R1 i R2 kao što je definisano, ovaj pronalazak se dalje odnosi na farmaceutske smeše koje sadrže i postupke za uzpotrebu jedinjenja formule (I) ili njene farmaceutski prihvatljive soli za inhibiciju fosfodiasteraeze (PDE) tipa IV ili javljanja faktora nekroze tumora (TNF) kod sisara.
YU60198A 1996-06-25 1998-12-24 Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf) YU60198A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (1)

Publication Number Publication Date
YU60198A true YU60198A (sh) 1999-09-27

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
YU60198A YU60198A (sh) 1996-06-25 1998-12-24 Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf)

Country Status (42)

Country Link
US (1) US6040329A (sh)
EP (1) EP0912558B1 (sh)
JP (1) JP3152940B2 (sh)
KR (1) KR20000022516A (sh)
CN (1) CN1080260C (sh)
AP (1) AP1025A (sh)
AR (1) AR007456A1 (sh)
AT (1) ATE244713T1 (sh)
AU (1) AU716376B2 (sh)
BG (1) BG64052B1 (sh)
BR (1) BR9712782A (sh)
CA (1) CA2258285C (sh)
CO (1) CO4900056A1 (sh)
CZ (1) CZ423398A3 (sh)
DE (1) DE69723447T2 (sh)
DK (1) DK0912558T3 (sh)
DZ (1) DZ2254A1 (sh)
EA (1) EA002274B1 (sh)
ES (1) ES2201299T3 (sh)
GT (1) GT199700075A (sh)
HN (1) HN1997000079A (sh)
HR (1) HRP970350B1 (sh)
HU (1) HUP9903009A3 (sh)
ID (1) ID18579A (sh)
IL (1) IL127036A (sh)
IS (1) IS4910A (sh)
MA (1) MA24225A1 (sh)
MY (1) MY116915A (sh)
NO (1) NO986103L (sh)
NZ (1) NZ332752A (sh)
OA (1) OA10934A (sh)
PA (1) PA8432301A1 (sh)
PL (1) PL330974A1 (sh)
PT (1) PT912558E (sh)
SI (1) SI0912558T1 (sh)
SK (1) SK176598A3 (sh)
TN (1) TNSN97108A1 (sh)
TR (1) TR199802685T2 (sh)
TW (1) TW434237B (sh)
WO (1) WO1997049702A1 (sh)
YU (1) YU60198A (sh)
ZA (1) ZA975581B (sh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
NZ334213A (en) * 1996-09-04 2000-08-25 Pfizer Indazole derivatives as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) for treating asthma, arthritis, bronchitis, CNS disorders
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
SK6252000A3 (en) * 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
NZ503995A (en) * 1997-11-04 2003-02-28 Pfizer Prod Inc Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
CA2469939C (en) 2001-12-14 2012-06-19 Applied Research Systems Ars Holding N.V. Method of inducing ovulation using a non-polypeptide camp level modulator
RU2368604C2 (ru) 2002-07-19 2009-09-27 Мемори Фармасьютиклз Корпорейшн Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
CA2492911A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
KR20050075430A (ko) 2002-11-19 2005-07-20 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제
CN1809559B (zh) * 2003-04-18 2010-06-02 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CA2584317A1 (en) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
EP1891060A2 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited 3-indazolyl-isoxazoline derivatives as inhibitors of phosphodiesterase type-iv
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2124944B1 (en) 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2493889B1 (en) * 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (sh) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
MX9301943A (es) * 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
JPH09511758A (ja) * 1994-10-20 1997-11-25 フアイザー・インコーポレイテツド 二環式テトラヒドロピラゾロピリジンおよび医薬としてのその使用

Also Published As

Publication number Publication date
AP9701020A0 (en) 1997-07-31
GT199700075A (es) 1998-12-04
EP0912558B1 (en) 2003-07-09
BG64052B1 (bg) 2003-11-28
HUP9903009A3 (en) 2002-01-28
SK176598A3 (en) 2000-06-12
PT912558E (pt) 2003-11-28
TNSN97108A1 (fr) 2005-03-15
AR007456A1 (es) 1999-10-27
BG103056A (en) 1999-10-29
CN1080260C (zh) 2002-03-06
CO4900056A1 (es) 2000-03-27
EP0912558A1 (en) 1999-05-06
DE69723447T2 (de) 2003-12-24
ATE244713T1 (de) 2003-07-15
DE69723447D1 (de) 2003-08-14
ES2201299T3 (es) 2004-03-16
HK1018700A1 (en) 1999-12-30
JP3152940B2 (ja) 2001-04-03
CA2258285A1 (en) 1997-12-31
EA002274B1 (ru) 2002-02-28
AU2785797A (en) 1998-01-14
DK0912558T3 (da) 2003-08-18
NO986103D0 (no) 1998-12-23
EA199801047A1 (ru) 1999-06-24
ZA975581B (en) 1998-12-24
HN1997000079A (es) 1997-12-26
IS4910A (is) 1998-11-27
HUP9903009A2 (hu) 2000-05-28
NO986103L (no) 1998-12-23
ID18579A (id) 1998-04-23
PL330974A1 (en) 1999-06-21
IL127036A0 (en) 1999-09-22
CN1223651A (zh) 1999-07-21
CZ423398A3 (cs) 1999-12-15
AU716376B2 (en) 2000-02-24
SI0912558T1 (en) 2003-10-31
HRP970350B1 (en) 2003-04-30
KR20000022516A (ko) 2000-04-25
US6040329A (en) 2000-03-21
PA8432301A1 (es) 1999-12-27
OA10934A (en) 2002-02-18
BR9712782A (pt) 1999-12-07
AP1025A (en) 2001-11-19
DZ2254A1 (fr) 2002-12-18
WO1997049702A1 (en) 1997-12-31
TW434237B (en) 2001-05-16
CA2258285C (en) 2002-11-26
HRP970350A2 (en) 1998-06-30
JPH11514668A (ja) 1999-12-14
MA24225A1 (fr) 1997-12-31
MY116915A (en) 2004-04-30
TR199802685T2 (xx) 1999-03-22
NZ332752A (en) 2001-04-27
IL127036A (en) 2001-06-14

Similar Documents

Publication Publication Date Title
YU60198A (sh) Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf)
YU16397A (sh) Supstituisani derivati indazola i srodna jedinjenja
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
YU35697A (sh) Supstituisani 6,6-hetero-biciklični derivati
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
EP0353955A3 (en) Novel compounds
ES2157314T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
EA200501104A1 (ru) Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
YU31995A (sh) Benzotiofeni glikopiranozida, postupak za njihovo dobijanje i njihova farmaceutska formulacija
YU140391A (sh) 6-supstituisani-heksahidrobenz (cd)-indoli
DK0635012T3 (da) Bis-aryl-carbinolderivater uden broer, præparater indeholdende disse og fremgangsmåder til anvendelse af disse
ES543782A0 (es) Procedimiento de preparacion de un derivado 1,1-difenilpro- pan-1-ol